Results 281 to 290 of about 93,087 (311)

Allogeneic hematopoietic stem cell transplantation for myelofibrosis

Current Opinion in Hematology, 2006
This review summarizes the current status and new developments in allogeneic hemopoietic stem cell transplantation strategies for patients with myelofibrosis with myeloid metaplasia, focusing on novel concepts of allogeneic transplantation with reduced-intensity conditioning.No substantial progress has been made in the conventional management of ...
Giovanni, Barosi, Andrea, Bacigalupo
openaire   +2 more sources

Allogeneic Stem Cell Transplantation for Thalassemia Major

Hematology/Oncology Clinics of North America, 2014
Allogeneic stem cell transplant remains the only curative option for β-thalassemia major. In patients with good risk features it is reasonable to anticipate a greater than 90% chance of a successful transplant outcome. The conventional risk stratification system has limitations and alternative systems are being explored to better identify subsets that ...
Vikram, Mathews, Alok, Srivastava, Mammen, Chandy   +2 more
openaire   +2 more sources

Novel approaches in allogeneic stem cell transplantation

Current Oncology Reports, 2006
Allogeneic transplantation remains an integral part of the management of hematologic malignancies. However, transplant-related mortality, graft-versus-host disease, and disease recurrence continue to be major limitations to successful transplant outcomes and challenges to investigators in the field.
Esperanza B, Papadopoulos, Ann A, Jakubowski   +1 more
openaire   +2 more sources

Allogeneic Stem Cell Transplantation

2003
Part I. Historical Perspective Hematopoietic Stem Cell Transplantation: A Historical Perspective Frederick R. Appelbaum Part II. Disease Indications: Allogeneic Transplantation Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Acute Myelogenous Leukemia Henry C. Fung and Stephen J.
openaire   +1 more source

Allogeneic Stem Cell Transplantation

2013
The survival of patients with multiple myeloma (MM) has improved over the past decade [1]. The most significant gains have been in patients without high-risk molecular markers. Despite these gains, multiple myeloma remains fatal and curative strategies are needed.
openaire   +1 more source

Current practice in nutrition after allogeneic hematopoietic stem cell transplantation – Results from a survey among hematopoietic stem cell transplant centers

Clinical Nutrition, 2021
H Greinix, Inken Hilgendorf, Christoph Schmid   +2 more
exaly  

Allogeneic stem cell transplantation

2004
Paul Veys, Kanchan Rao
openaire   +2 more sources

Adenovirus infection after allogeneic stem cell transplantation

Leukemia and Lymphoma, 2007
Tobias Feuchtinger, Peter Lang, Rupert Handgretinger   +2 more
exaly  

Stem cell transplantation allogeneic

The Hematology Journal, 2004
openaire   +2 more sources

T Cell Recruitment to the Intestinal Stem Cell Compartment Drives Immune-Mediated Intestinal Damage after Allogeneic Transplantation

Immunity, 2019
Ya-Yuan Fu, Jason Kuttiyara, Marco Calafiore   +2 more
exaly